EGFR and non-small cell lung carcinoma: Together, positive CNS activity observed with these EGFR TKIs suggests that incorporation of EGFR TKIs in the treatment of asymptomatic brain metastases from EGFR-mutant NSCLC appears reasonable and these agents may be utilized upfront and radiation therapy reserved until progression to avoid radiation related neurotoxicity.